Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Jan 25, 2027 (in 102 days)
Similar opportunities open now
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Oct 19, 2026Up to $600K
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 26 days)Up to $150K
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Nov 2029Up to $600K
- Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses May 2027Up to $500K
- NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses May 2029
Classification and identifiers
- Solicitation number
- PAR-28-062
- Assistance listing (CFDA)
- 93.399
Amount
Amount not listed here. Check the official program.
Who can apply
Small businesses, Local government agencies, and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsEligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations.
About this opportunity
This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health (CPACH) Program. The CPACH Program develops and maintains comprehensive, long-term, mutually beneficial partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and addresses challenges in cancer research, including a focus on advancing research on health drivers that contribute to differences in cancer outcomes across all populations, as well as cancer outreach and engagement.